Literature DB >> 15233367

Antiretroviral treatment of maternal HIV infection.

Haleh Talaie1, Alejandro A Nava-Ocampo, Gideon Koren.   

Abstract

QUESTION: One of my pregnant patients tested positive for human immunodeficiency virus. Will HIV therapy put her pregnancy outcome at risk? ANSWER: The biggest risk is vertical transmission of HIV to her baby. She should be treated with combination therapy; triple therapy is required to reduce vertical transmission. Zidovudine is not teratogenic in humans, but information on other antiretroviral drugs is incomplete.

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15233367      PMCID： PMC2214614     

Source DB:  PubMed          Journal:  Can Fam Physician        ISSN： 0008-350X            Impact factor:   3.275


  34 in total

1.  Protease inhibitor treatment in HIV pregnant women. Is it safe for newborns?

Authors:  A García-Tejedor; A Perales; V Maiques
Journal:  Int J Gynaecol Obstet       Date:  2002-02       Impact factor: 3.561

2.  Risk factors for preterm birth, low birth weight, and intrauterine growth retardation in infants born to HIV-infected pregnant women receiving zidovudine. Pediatric AIDS Clinical Trials Group 185 Team.

Authors:  J S Lambert; D H Watts; L Mofenson; E R Stiehm; D R Harris; J Bethel; J Whitehouse; E Jimenez; J Gandia; G Scott; M J O'Sullivan; A Kovacs; A Stek; W T Shearer; H Hammill; R van Dyke; R Maupin; M Silio; M G Fowler
Journal:  AIDS       Date:  2000-07-07       Impact factor: 4.177

3.  Lamivudine-zidovudine combination for prevention of maternal-infant transmission of HIV-1.

Authors:  L Mandelbrot; A Landreau-Mascaro; C Rekacewicz; A Berrebi; J L Bénifla; M Burgard; E Lachassine; B Barret; M L Chaix; A Bongain; N Ciraru-Vigneron; C Crenn-Hébert; J F Delfraissy; C Rouzioux; M J Mayaux; S Blanche
Journal:  JAMA       Date:  2001-04-25       Impact factor: 56.272

4.  Combination antiretroviral strategies for the treatment of pregnant HIV-1-infected women and prevention of perinatal HIV-1 transmission.

Authors:  Ellen R Cooper; Manhattan Charurat; Lynne Mofenson; I Celine Hanson; Jane Pitt; Clemente Diaz; Karen Hayani; Edward Handelsman; Vincent Smeriglio; Rodney Hoff; William Blattner
Journal:  J Acquir Immune Defic Syndr       Date:  2002-04-15       Impact factor: 3.731

5.  Maternal characteristics associated with antenatal, intrapartum, and neonatal zidovudine use in four US cities, 1994-1998.

Authors:  S L Orloff; M Bulterys; P Vink; S Nesheim; E J Abrams; E Schoenbaum; P Palumbo; R W Steketee; R J Simonds
Journal:  J Acquir Immune Defic Syndr       Date:  2001-09-01       Impact factor: 3.731

6.  Efficacy of three short-course regimens of zidovudine and lamivudine in preventing early and late transmission of HIV-1 from mother to child in Tanzania, South Africa, and Uganda (Petra study): a randomised, double-blind, placebo-controlled trial.

Authors: 
Journal:  Lancet       Date:  2002-04-06       Impact factor: 79.321

Review 7.  Liver disease in pregnancy and fetal fatty acid oxidation defects.

Authors:  J A Ibdah; Z Yang; M J Bennett
Journal:  Mol Genet Metab       Date:  2000 Sep-Oct       Impact factor: 4.797

8.  Guidelines for using antiretroviral agents among HIV-infected adults and adolescents. Recommendations of the Panel on Clinical Practices for Treatment of HIV.

Authors:  Mark Dybul; Anthony S Fauci; John G Bartlett; Jonathan E Kaplan; Alice K Pau
Journal:  MMWR Recomm Rep       Date:  2002-05-17

9.  Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET 012).

Authors:  S H Eshleman; M Mracna; L A Guay; M Deseyve; S Cunningham; M Mirochnick; P Musoke; T Fleming; M Glenn Fowler; L M Mofenson; F Mmiro; J B Jackson
Journal:  AIDS       Date:  2001-10-19       Impact factor: 4.177

10.  Antiretroviral therapy during pregnancy and the risk of an adverse outcome.

Authors:  Ruth E Tuomala; David E Shapiro; Lynne M Mofenson; Yvonne Bryson; Mary Culnane; Michael D Hughes; M J O'Sullivan; Gwendolyn Scott; Alice M Stek; Diane Wara; Marc Bulterys
Journal:  N Engl J Med       Date:  2002-06-13       Impact factor: 91.245
View more
  1 in total

1.  HIV Prophylaxis in High Risk Newborns: An Examination of Sociodemographic Factors in an Inner City Context.

Authors:  Zenita Alidina; Anne E Wormsbecker; Marcelo Urquia; Jay MacGillivray; Evan Taerk; Mark H Yudin; Douglas M Campbell
Journal:  Can J Infect Dis Med Microbiol       Date:  2016-04-03       Impact factor: 2.471
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.